Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis
Open Access
- 3 May 2013
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (10), 3820-3832
- https://doi.org/10.1021/jm400349k
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Pharmacological Validation of Trypanosoma brucei Phosphodiesterases as Novel Drug TargetsThe Journal of Infectious Diseases, 2012
- Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping SicknessJournal of Medicinal Chemistry, 2011
- Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African TrypanosomiasisAntimicrobial Agents and Chemotherapy, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety AttributesACS Chemical Neuroscience, 2010
- Targeting protein kinases in central nervous system disordersNature Reviews Drug Discovery, 2009
- The Phosphoproteome of Bloodstream Form Trypanosoma brucei, Causative Agent of African Sleeping SicknessMolecular & Cellular Proteomics, 2009
- Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic miceProceedings of the National Academy of Sciences, 2008
- Analysis of the Trypanosoma brucei cell cycle by quantitative DAPI imagingMolecular and Biochemical Parasitology, 2008
- Cell cycle regulation in Trypanosoma bruceiMolecular and Biochemical Parasitology, 2007